TELA logo

TELA
TELA Bio Inc

316
Mkt Cap
$26.72M
Volume
164,951.00
52W High
$2.20
52W Low
$0.5011
PE Ratio
-0.72
TELA Fundamentals
Price
$0.6316
Prev Close
$0.5973
Open
$0.5982
50D MA
$0.8079
Beta
0.83
Avg. Volume
155,033.54
EPS (Annual)
-$0.8271
P/B
4.21
Rev/Employee
$368,233.95
$62.21
Loading...
Loading...
News
all
press releases
TELA Bio Analysts Cut Their Forecasts After Q4 Results
TELA Bio (NASDAQ:TELA) reported mixed Q4 results, with higher losses but lower sales than expected. Analysts lowered price targets for the stock.read more...
Benzinga·12d ago
News Placeholder
More News
News Placeholder
Amazon To Rally Around 49%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC Wainwright, Susquehanna, Raymond James and Goldman Sachs adjust price targets for companies like...
Benzinga·12d ago
News Placeholder
TELA Bio (TELA) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·13d ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of +11.11% and -0.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +586.28% and +300.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of +252.25% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika (ANIK) delivered earnings and revenue surprises of +1,450.00% and +6.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly
TELA Bio is suing Becton Dickinson for allegedly abusing its monopoly power in the hernia mesh market to limit competition and harm patients.read more...
Benzinga·3mo ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +17.65% and -17.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
<
1
2
...
>

Latest TELA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.